Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography

Khalil, Hossam El Din; Ahmed, Abdel Rahman Shaaban; Mahfouz Eliwa, Hassan Mostafa

doi:10.21608/ejmr.2022.240903

Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography

Document Type : Original Article

Authors

Department of Ophthalmology, Faculty of Medicine, Beni-Suef University

10.21608/ejmr.2022.240903

Abstract

Background: Diabetic macular edema (DME) can occur at any stage of non-proliferative and proliferative diabetic retinopathy. It is characterized by a swelling of the macular area that normally accounts for high-resolution visual acuity (VA), and DME therefore leads to visual deterioration.
Objective: To compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. Patients and Methods: This was a prospective comparative study conducted on 32 Diabetic macular edema (DME); to compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. Results: Pre-operative BCVA had a highly significant positive correlation with post-operative BCVA (p < 0.0001). DM duration had a highly significant negative correlation with post-operative BCVA (p = 0.0002). Logistic regression analysis shows that; after applying (Forward method) and entering some predictor variables; the decrease in DM duration; had an independent effect on increasing the probability of patient’s visual acuity improvement; with significant statistical difference (p = 0.042). By using ROC-curve analysis, Aflibercept and Ranibizumab usage showed non-significant predictive values in discrimination of improved patients from patients worsened ones (p > 0.05). Conclusion: Both aflibercept and ranibizumab improve visual acuity and decrease CMT in eyes with DME and moderate visual loss with no difference between the two drugs.

Keywords

Main Subjects

Surgery ·

References

Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S (2012): Global prevalence and major risk factors of diabetic retinopathy. Diabetes care. 35(3):556-64.
Mansour AM, Dedhia C, Chhablani J (2017): Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema. British Journal of Ophthalmology, 101(2): 166-169.
Lang GE (2012): Diabetic macular edema. Ophthalmologica, 227(Suppl. 1): 21-29.
Bhagat N, Grigorian RA, Tutela A, Zarbin MA (2009): Diabetic macular edema: pathogenesis and treatment. Survey of ophthalmology, 54(1): 1-32.
Jampol LM, Bressler NM, Glassman AR (2014): Revolution to a new standard treatment of diabetic macular edema. Jama, 311(22): 2269-2270.
Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE (2016): Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice. JAMA Ophthalmology, 134(1): 95–99.
Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD (2015): Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 122(10):2044-52.
Fauser S & Muether PS (2016): Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. British Journal of Ophthalmology, 100(11): 1494–1498.
Babiuch AS, Conti TF, Conti FF, Silva FQ, Rachitskaya A, Yuan A, Singh RP (2019): Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis. International Journal of Retina and Vitreous, 5(1): 17.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A (2019): Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: A randomized clinical trial. JAMA Ophthalmology, 137(11): 1256–1264.
Khurana RN, Chang LK, Bansal AS, Palmer JD, Wu C, Wieland MR (2018): Aflibercept for previously treated macular edema associated with central retinal vein occlusions: 1-year results of the NEWTON Study. Ophthalmology Retina, 2(2): 128–133.
Fouda SM & Bahgat AM (2017): Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clinical Ophthalmology (Auckland, NZ): 11, 567.
Network DRCR (2015): Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine, 372(13): 1193–1203.
Strong SA, Gurbaxani A, Michaelides M (2016): Treatment of retinitis pigmentosa-associated cystoid macular oedema using intravitreal aflibercept (Eylea) despite minimal response to ranibizumab (Lucentis): A case report. Case Reports in Ophthalmology, 7(2): 389–397.
Plaza-Ramos P, Borque E, García-Layana A (2019): Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice. PLoS One, 14(10): e0223793.
Moustafa GA & Moschos MM (2015): Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa-a first case report and short review of the literature. BMC Ophthalmology, 15(1): 1–6.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C (2016): Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology, 123(6): 1351–1359.
Klein KA, Cleary TS, Reichel E (2017): Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. International Journal of Retina and Vitreous, 3(1): 16.
Régnier SA, Malcolm W, Haig J, Xue W (2015): Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: A UK healthcare perspective. ClinicoEconomics and Outcomes Research: CEOR, 7, 235.